Actively Recruiting
Study of Colchicine to Prevent Recurrence of Brain Bleeding in Patients with Cerebral Amyloid Angiopathy A Phase II Randomized Trial Comparing Colchicine and Placebo Over One Year
Led by Huashan Hospital · Updated on 2025-06-26
80
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and tolerability of colchicine for preventing recurrence of intracerebral hemorrhage ICH in patients with cerebral amyloid angiopathy CAA who are at high risk of another ICH. This phase II randomized, double-blind, placebo-controlled trial aims to compare colchicine to a placebo to see if it is safe, well tolerated, and potentially effective in reducing ICH recurrence. Participants will be randomly assigned to take either oral colchicine 0.5 mg once daily or a matching placebo for one year, alongside standard care including blood pressure control and lifestyle changes. Follow-up visits will occur at 3, 6, 9, and 12 months, during which adverse events, medication adherence, and clinical outcomes will be assessed. During the study, participants will have telephone follow-ups at 3 and 9 months, and clinic visits at 6 and 12 months for checkups and tests including brain MRI scans. Researchers will monitor treatment-emergent adverse events, treatment tolerability, clinical efficacy outcomes like ICH recurrence, cognitive and functional outcomes, quality of life, and blood inflammatory markers. The total participation duration is one year.
CONDITIONS
Brief Title
Colchicine for the Prevention of Recurrence in Cerebral Amyloid Angiopathy RElated IntraCerebral Hemorrhage
Research Team
X
Xin Cheng, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here